logo
#

Latest news with #LaboratoriosFarmaceuticosRovi

European Stocks That May Be Priced Below Their Estimated Intrinsic Values
European Stocks That May Be Priced Below Their Estimated Intrinsic Values

Yahoo

time03-06-2025

  • Business
  • Yahoo

European Stocks That May Be Priced Below Their Estimated Intrinsic Values

As European markets experience a slight uptick, with the pan-European STOXX Europe 600 Index rising by 0.65% amid trade negotiations and slowing inflation, investors are keenly observing potential shifts in monetary policy from the European Central Bank. In this environment, identifying stocks that may be priced below their estimated intrinsic values can offer opportunities for those looking to capitalize on market inefficiencies and economic developments. Name Current Price Fair Value (Est) Discount (Est) Laboratorios Farmaceuticos Rovi (BME:ROVI) €53.90 €104.47 48.4% Alfio Bardolla Training Group (BIT:ABTG) €1.90 €3.70 48.6% CTT Systems (OM:CTT) SEK213.50 SEK416.33 48.7% Séché Environnement (ENXTPA:SCHP) €99.00 €197.26 49.8% Clemondo Group (OM:CLEM) SEK10.80 SEK21.25 49.2% Lectra (ENXTPA:LSS) €24.05 €47.11 49% Absolent Air Care Group (OM:ABSO) SEK214.00 SEK416.45 48.6% Trøndelag Sparebank (OB:TRSB) NOK114.50 NOK226.55 49.5% Nexstim (HLSE:NXTMH) €7.98 €15.71 49.2% VIGO Photonics (WSE:VGO) PLN522.00 PLN1042.74 49.9% Click here to see the full list of 187 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's dive into some prime choices out of the screener. Overview: Maire S.p.A. specializes in developing and implementing solutions for the energy transition, with a market cap of €3.76 billion. Operations: The company's revenue segments consist of Integrated E&C Solutions, generating €5.97 billion, and Sustainable Technology Solutions, contributing €376.94 million. Estimated Discount To Fair Value: 35.8% Maire S.p.A. appears undervalued, trading 35.8% below its estimated fair value of €17.83, with a current price of €11.45. Recent earnings growth and a forecasted annual profit increase of 12.4% outpace the Italian market's average growth rate, despite revenue projections being modest at 5.9%. The company's recent strategic partnership with Radware enhances its cybersecurity offerings, potentially bolstering future cash flows amidst a volatile share price history and an unstable dividend track record. Our expertly prepared growth report on Maire implies its future financial outlook may be stronger than recent results. Click here and access our complete balance sheet health report to understand the dynamics of Maire. Overview: Cellnex Telecom, S.A. operates as a manager of terrestrial telecommunications infrastructures across multiple European countries including Austria, Denmark, Spain, and others, with a market cap of €23.98 billion. Operations: Cellnex Telecom generates revenue through the management of terrestrial telecommunications infrastructures across several European countries, including Austria, Denmark, Spain, and others. Estimated Discount To Fair Value: 44.1% Cellnex Telecom is trading at €33.98, significantly below its estimated fair value of €60.77, indicating it is undervalued based on cash flows. The company is forecast to achieve profitability within three years, with earnings expected to grow by 49.35% annually. Recent strategic moves include a completed share buyback worth €800 million and potential sale discussions of its Swiss business for up to €2 billion, which could influence future cash flow dynamics positively. Our earnings growth report unveils the potential for significant increases in Cellnex Telecom's future results. Click to explore a detailed breakdown of our findings in Cellnex Telecom's balance sheet health report. Overview: Thales S.A. operates globally in the defence and security, aerospace and space, and digital identity and security sectors, with a market cap of €55.48 billion. Operations: Thales generates revenue from its Aerospace segment (€5.64 billion), Cyber & Digital operations (€4.15 billion), and Defence (excluding Digital Identity & Security) activities (€11.32 billion). Estimated Discount To Fair Value: 15.8% Thales is trading at €270.2, below its estimated fair value of €321.06, showing it is undervalued based on cash flows. Earnings are forecast to grow 17.94% annually, outpacing the French market's growth rate. Recent strategic partnerships with Michelin and Deloitte enhance Thales's position in software monetization and cybersecurity services, potentially bolstering future cash flow generation while maintaining a focus on selective mergers and acquisitions for strategic expansion. Insights from our recent growth report point to a promising forecast for Thales' business outlook. Navigate through the intricacies of Thales with our comprehensive financial health report here. Delve into our full catalog of 187 Undervalued European Stocks Based On Cash Flows here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BIT:MAIRE BME:CLNX and ENXTPA:HO. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

European Value Stocks Priced Below Estimated Intrinsic Worth
European Value Stocks Priced Below Estimated Intrinsic Worth

Yahoo

time28-05-2025

  • Business
  • Yahoo

European Value Stocks Priced Below Estimated Intrinsic Worth

The European stock market has recently faced downward pressure, with the pan-European STOXX Europe 600 Index dropping by 0.75% amid heightened trade tensions following proposed tariffs from the U.S. administration. In this challenging environment, identifying stocks that are priced below their intrinsic value can offer investors potential opportunities to capitalize on market inefficiencies and position themselves for long-term gains. Name Current Price Fair Value (Est) Discount (Est) Micro Systemation (OM:MSAB B) SEK49.60 SEK96.51 48.6% Laboratorios Farmaceuticos Rovi (BME:ROVI) €52.35 €104.47 49.9% Alfio Bardolla Training Group (BIT:ABTG) €1.88 €3.70 49.2% adidas (XTRA:ADS) €220.50 €433.62 49.1% Clemondo Group (OM:CLEM) SEK10.80 SEK21.24 49.2% Absolent Air Care Group (OM:ABSO) SEK215.00 SEK416.92 48.4% Lectra (ENXTPA:LSS) €24.75 €47.27 47.6% dormakaba Holding (SWX:DOKA) CHF733.00 CHF1399.64 47.6% Claranova (ENXTPA:CLA) €2.805 €5.45 48.5% Northern Data (DB:NB2) €25.02 €49.53 49.5% Click here to see the full list of 182 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's dive into some prime choices out of the screener. Overview: A.L.A. società per azioni is a supply chain solutions provider serving the aerospace and defense, rail, and high-tech sectors with a market cap of €314.24 million. Operations: The company's revenue is primarily derived from its Distribution segment at €140.29 million, followed by Service Providers at €120.54 million, Production at €23.15 million, and On Site Assembly at €5.91 million. Estimated Discount To Fair Value: 26.7% A.L.A. società per azioni is trading at €34.8, significantly below its estimated fair value of €47.49, reflecting a potential undervaluation based on cash flows. Despite a high level of non-cash earnings and debt not well covered by operating cash flow, the company's earnings grew 71.7% last year and are forecast to grow 22.3% annually, outpacing the Italian market's growth rate of 7.4%. Our earnings growth report unveils the potential for significant increases in A.L.A. società per azioni's future results. Click here and access our complete balance sheet health report to understand the dynamics of A.L.A. società per azioni. Overview: Datalogic S.p.A. is a company that produces and distributes automatic data capture and process automation products across various regions including Italy, the Americas, the Asia Pacific, Europe, the Middle East, and Africa with a market cap of €248.65 million. Operations: Datalogic's revenue is primarily derived from two segments: Data Capture, contributing €338.70 million, and Industrial Automation, generating €156.49 million. Estimated Discount To Fair Value: 15% Datalogic is trading at €4.64, 15% below its estimated fair value of €5.45, indicating potential undervaluation based on cash flows. Despite a recent quarterly net loss of €5.86 million and declining profit margins, earnings are projected to grow significantly at 57.72% annually over the next three years, outpacing both revenue growth and the Italian market's earnings growth rate of 7.4%. However, its dividend yield of 2.59% is not well covered by earnings or free cash flows. According our earnings growth report, there's an indication that Datalogic might be ready to expand. Unlock comprehensive insights into our analysis of Datalogic stock in this financial health report. Overview: Cicor Technologies Ltd., along with its subsidiaries, develops and manufactures electronic components, devices, and systems globally, with a market cap of CHF548.70 million. Operations: The company's revenue segments include the Advanced Substrates (AS) Division, generating CHF45.31 million, and the Electronic Manufacturing Services (EMS) Division, contributing CHF438.01 million. Estimated Discount To Fair Value: 12.2% Cicor Technologies, trading at CHF126, is slightly undervalued based on discounted cash flow analysis with an estimated fair value of CHF143.47. Despite recent shareholder dilution and high share price volatility, earnings are expected to grow significantly at 21.48% annually over the next three years, surpassing Swiss market averages. Recent strategic moves include a supply agreement with Mercury Mission Systems to enhance its European aerospace and defense presence, potentially boosting future revenue streams. Insights from our recent growth report point to a promising forecast for Cicor Technologies' business outlook. Take a closer look at Cicor Technologies' balance sheet health here in our report. Click through to start exploring the rest of the 179 Undervalued European Stocks Based On Cash Flows now. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BIT:ALA BIT:DAL and SWX:CICN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

European Value Stocks: 3 Companies Trading Below Estimated Worth
European Value Stocks: 3 Companies Trading Below Estimated Worth

Yahoo

time28-05-2025

  • Business
  • Yahoo

European Value Stocks: 3 Companies Trading Below Estimated Worth

The European stock market recently faced a downturn, with the pan-European STOXX Europe 600 Index ending lower after five weeks of gains, influenced by new tariff threats from the U.S. and unexpected contractions in business activity. In this environment, investors might look for value opportunities in stocks trading below their estimated worth, as these can offer potential resilience and growth despite broader market challenges. Name Current Price Fair Value (Est) Discount (Est) Micro Systemation (OM:MSAB B) SEK49.60 SEK96.51 48.6% Laboratorios Farmaceuticos Rovi (BME:ROVI) €52.35 €104.47 49.9% Alfio Bardolla Training Group (BIT:ABTG) €1.88 €3.70 49.2% adidas (XTRA:ADS) €220.50 €433.62 49.1% Clemondo Group (OM:CLEM) SEK10.80 SEK21.24 49.2% Absolent Air Care Group (OM:ABSO) SEK215.00 SEK416.92 48.4% Lectra (ENXTPA:LSS) €24.75 €47.27 47.6% dormakaba Holding (SWX:DOKA) CHF733.00 CHF1399.64 47.6% Fodelia Oyj (HLSE:FODELIA) €7.00 €13.31 47.4% Claranova (ENXTPA:CLA) €2.805 €5.45 48.5% Click here to see the full list of 181 stocks from our Undervalued European Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: REVO Insurance S.p.A. is an Italian insurance company with a market cap of €378.54 million. Operations: The company's revenue primarily comes from its Damage Management segment, which generated €317.62 million. Estimated Discount To Fair Value: 27.6% REVO Insurance is trading at a significant discount, approximately €14.96 compared to its estimated fair value of €20.65, suggesting undervaluation based on discounted cash flow analysis. The company reported a substantial net income increase to €18.58 million for 2024 and forecasts strong earnings growth of 24.3% annually over the next three years, outpacing the Italian market's average growth rate, despite having a forecasted low return on equity of 14.4%. Upon reviewing our latest growth report, REVO Insurance's projected financial performance appears quite optimistic. Dive into the specifics of REVO Insurance here with our thorough financial health report. Overview: BlueNord ASA is an oil and gas company engaged in the exploration, development, and production of hydrocarbon resources across Norway, Denmark, the Netherlands, and the United Kingdom with a market cap of NOK15.42 billion. Operations: The company's revenue from its oil and gas exploration and production activities amounts to $704.90 million. Estimated Discount To Fair Value: 31.1% BlueNord is trading at NOK582, significantly below its estimated fair value of NOK844.91, indicating potential undervaluation based on discounted cash flow analysis. Recent earnings show a turnaround with net income rising to US$18.6 million from a loss last year, and revenue reaching US$171.1 million for Q1 2025. Despite interest payments not well covered by earnings, production ramp-up at Tyra II supports future profitability expectations above market growth rates in Norway. The growth report we've compiled suggests that BlueNord's future prospects could be on the up. Delve into the full analysis health report here for a deeper understanding of BlueNord. Overview: PSI Software SE develops and integrates software solutions to optimize energy and materials flow for utilities and industry globally, with a market cap of €461.54 million. Operations: The company's revenue is primarily derived from Process Industries & Metals (€72.15 million), Logistics (€33.77 million), and Discrete Manufacturing (€31.70 million). Estimated Discount To Fair Value: 33.6% PSI Software is trading at €29.8, well below its estimated fair value of €44.87, highlighting potential undervaluation based on discounted cash flow analysis. The company reported a significant improvement in Q1 2025 earnings with sales rising to €67.9 million and net income turning positive at €0.271 million from a substantial loss last year. With expected revenue growth outpacing the German market and a strategic partnership with Google Cloud, PSI is positioned for enhanced operational efficiency and profitability over the next three years. Insights from our recent growth report point to a promising forecast for PSI Software's business outlook. Click here and access our complete balance sheet health report to understand the dynamics of PSI Software. Click here to access our complete index of 181 Undervalued European Stocks Based On Cash Flows. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BIT:REVO OB:BNOR and XTRA:PSAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

European Value Stocks: 3 Companies Estimated Below Intrinsic Worth
European Value Stocks: 3 Companies Estimated Below Intrinsic Worth

Yahoo

time21-05-2025

  • Business
  • Yahoo

European Value Stocks: 3 Companies Estimated Below Intrinsic Worth

Amid a recent improvement in sentiment following the de-escalation of trade tensions between the U.S. and China, European markets have seen a positive uptick, with key indices like Germany's DAX and France's CAC 40 showing gains. In this environment of cautious optimism, identifying stocks that are potentially undervalued can be particularly appealing for investors seeking opportunities; these stocks may offer intrinsic value not fully recognized by current market prices. Name Current Price Fair Value (Est) Discount (Est) Laboratorios Farmaceuticos Rovi (BME:ROVI) €52.75 €105.29 49.9% Airbus (ENXTPA:AIR) €161.84 €322.14 49.8% adidas (XTRA:ADS) €220.70 €439.05 49.7% Lectra (ENXTPA:LSS) €23.75 €47.40 49.9% Absolent Air Care Group (OM:ABSO) SEK214.00 SEK417.39 48.7% Boreo Oyj (HLSE:BOREO) €15.65 €30.99 49.5% Lumibird (ENXTPA:LBIRD) €11.90 €23.51 49.4% Claranova (ENXTPA:CLA) €2.82 €5.47 48.4% BHG Group (OM:BHG) SEK27.20 SEK53.71 49.4% HBX Group International (BME:HBX) €9.90 €19.37 48.9% Click here to see the full list of 183 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's explore several standout options from the results in the screener. Overview: Bittium Oyj is a company that offers communications and connectivity solutions, healthcare technology products and services, as well as biosignal measuring and monitoring across Finland, Germany, and the United States with a market cap of €243.08 million. Operations: The company's revenue segments include €29.80 million from medical, €51.60 million from defense and security, and €14.32 million from engineering services. Estimated Discount To Fair Value: 21.4% Bittium Oyj is trading at €6.85, significantly below its estimated fair value of €8.71, indicating potential undervaluation based on cash flows. Despite recent share price volatility, the company projects strong earnings growth of 20.45% annually over the next three years, outpacing the Finnish market's growth rate. However, revenue growth is expected to be moderate at 10.2% annually and return on equity remains forecasted low at 9.5%. Recent dividend approval and stable guidance further support its financial outlook. Our growth report here indicates Bittium Oyj may be poised for an improving outlook. Navigate through the intricacies of Bittium Oyj with our comprehensive financial health report here. Overview: Yubico AB offers authentication solutions for computers, networks, and online services with a market cap of SEK13.12 billion. Operations: Unfortunately, the provided text does not include specific revenue segment information for Yubico AB. Therefore, I am unable to summarize the company's revenue segments in a sentence. Estimated Discount To Fair Value: 11.4% Yubico, trading at SEK 152.05, is undervalued with an estimated fair value of SEK 171.64. Despite a recent dip in net income to SEK 51.3 million from SEK 73.8 million last year, Yubico's revenue growth forecast exceeds the Swedish market average significantly at over 20% annually. The company's strategic expansion of YubiKey services across the EU and globally enhances its market position and could drive future cash flow improvements amidst strong analyst consensus on price appreciation potential. Insights from our recent growth report point to a promising forecast for Yubico's business outlook. Click to explore a detailed breakdown of our findings in Yubico's balance sheet health report. Overview: Mobilezone holding ag, along with its subsidiaries, offers mobile and fixed-line telephony, television, and Internet services for various network operators in Germany and Switzerland, with a market cap of CHF523.95 million. Operations: The company's revenue segments consist of CHF731.96 million from Germany and CHF275.76 million from Switzerland. Estimated Discount To Fair Value: 29.1% Mobilezone holding ag, trading at CHF 12.14, is significantly undervalued with a fair value estimate of CHF 17.12. Despite a decline in net income to CHF 16.98 million from the previous year's CHF 48.09 million and lower profit margins, earnings are forecast to grow over 20% annually, outpacing the Swiss market average of 10.7%. However, high debt levels and negative shareholder equity pose risks to financial stability despite strong projected earnings growth. Upon reviewing our latest growth report, mobilezone holding ag's projected financial performance appears quite optimistic. Click here to discover the nuances of mobilezone holding ag with our detailed financial health report. Take a closer look at our Undervalued European Stocks Based On Cash Flows list of 183 companies by clicking here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include HLSE:BITTI OM:YUBICO and SWX:MOZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Kepler Capital Keeps Their Buy Rating on Laboratorios Farmaceuticos Rovi (0ILL)
Kepler Capital Keeps Their Buy Rating on Laboratorios Farmaceuticos Rovi (0ILL)

Business Insider

time10-05-2025

  • Business
  • Business Insider

Kepler Capital Keeps Their Buy Rating on Laboratorios Farmaceuticos Rovi (0ILL)

In a report released on May 8, Pablo de Renteria from Kepler Capital maintained a Buy rating on Laboratorios Farmaceuticos Rovi (0ILL – Research Report), with a price target of €90.00. The company's shares closed yesterday at €52.90. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, de Renteria is an analyst with an average return of -8.2% and a 40.94% success rate. Currently, the analyst consensus on Laboratorios Farmaceuticos Rovi is a Moderate Buy with an average price target of €77.75. The company has a one-year high of €93.90 and a one-year low of €45.58. Currently, Laboratorios Farmaceuticos Rovi has an average volume of 12.76K.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store